PRINCETON, W.Va. — WVU Medicine Princeton Community Hospital has announced new additions to its cancer care leadership as the hospital continues expanding oncology services and preparing for construction of a comprehensive cancer center.
Hospital officials introduced Dr. Mohammed Abdulhaleem on Tuesday as the new director of medical oncology at the WVU Cancer Institute at PCH. Abdulhaleem, a hematologist and medical oncologist, joins the medical staff after completing an advanced hematology fellowship at WVU Medicine.
PCH President and CEO Karen Bowling said Abdulhaleem’s recruitment marks another major step in strengthening cancer care across southern West Virginia and southwest Virginia.
“His expertise in hematology, medical oncology and precision medicine strengthens our exceptional team of cancer specialists,” Bowling said. “Combined with the advanced technologies we’ve introduced over the past two years and our plans to build a new comprehensive cancer center, Dr. Abdulhaleem’s arrival continues the transformation of cancer care for our region.”
Abdulhaleem brings extensive clinical and research experience in gastrointestinal, thoracic, neuro‑oncology and hematologic cancers. He has authored peer‑reviewed publications and presented research at national meetings, including the American Society of Clinical Oncology and the American Society of Hematology.
He will diagnose and treat patients with blood cancers, benign blood disorders, solid tumors, and will oversee chemotherapy, immunotherapy, targeted therapies, symptom management and survivorship care. He will also coordinate care with surgeons, radiation oncologists and other specialists.
Bowling also introduced Ashley Fleenor, PA‑C, who will care for oncology patients during hospitalizations. Fleenor has specialized in oncology care since 2019.
Bowling noted that PCH’s influence continues to grow statewide. Dr. David Mullins, a general surgeon specializing in surgical oncology, has been appointed State Chair for Cancer by the American College of Surgeons for a three‑year term.
Construction is underway on a $35 million, 24,000‑square‑foot comprehensive cancer center outside PCH’s North (Parkview) entrance. The facility will bring medical oncology, infusion services, radiation oncology, clinical trials and support services together in one location.
In recent months, PCH has introduced several advanced technologies, including Pluvicto radioligand therapy, THOR photobiomodulation therapy, and cooling cap therapy for chemotherapy‑related hair loss. The hospital is accredited by the American College of Surgeons Commission on Cancer as a Surgical Quality Partner.
For referrals, providers may call 304‑557‑1164 or fax clinical documentation to 304‑557‑1165.
